ARTICLE | Emerging Company Profile

Promethera: Liver Supply

Promethera: hepatic stem cells for liver genetic disorders and toxicology testing

August 9, 2010 7:00 AM UTC

A consistent shortage of human livers has limited the availability of the organs for transplantation and the ability for biomedical researchers to have a steady supply of hepatocytes for preclinical testing. Promethera Biosciences S.A. believes its human adult liver-derived mesenchymal stem cells can help solve both issues.

The company is developing the cells as a therapy for liver-related genetic disorders, and as a source of hepatocytes for preclinical metabolism and toxicology testing...